Compare HKD & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HKD | LXRX |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 547.4M |
| IPO Year | 2021 | 2000 |
| Metric | HKD | LXRX |
|---|---|---|
| Price | $1.52 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 590.1K | ★ 2.3M |
| Earning Date | 02-27-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.16 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $1.26 | $0.32 |
| 52 Week High | $5.47 | $1.83 |
| Indicator | HKD | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 50.52 |
| Support Level | $1.34 | $1.08 |
| Resistance Level | $1.69 | $1.65 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 35.94 | 30.88 |
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.